Altamira Therapeutics (CYTO) Provides Investor and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Altamira Therapeutics Provides Investor and Business Update
December 11, 2023 8:00 AM ESTHAMILTON, BERMUDA, Dec. 11, 2023 (GLOBE NEWSWIRE) --
Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ETPartial spin-off of Bentrio® business first step in transition to become pure play RNA delivery companyTransition expected to complete in 2024 through partnering of further legacy assetsSpending levels and cash burn aligned with strategic repositioning and to decrease significantly in 2024  Free of financial debt following early repayment of convertible loan  Expects to regain full compliance with Nasdaq continued listing rules through reverse splitHAMILTON, BERMUDA, Dec. 11, 2023 --... More
